47%
of the patients we refer to a site reach screening.33%
of the patients we referred signed the informed consent in 2025: 1 in every 3.59%
of the patients who reach screening get randomized.28%
of every patient we refer ends up randomized.Trusted by
Some of the sponsors and CROs we work with across Latin America. All trademarks shown belong to their respective owners.
Some of the sponsors and CROs we work with across Latin America. All trademarks shown belong to their respective owners.The challenge
Enrollment is the bottleneck of the study
The sites are active and the protocol approved, but the study does not move until the patients arrive.Timelines that stretch
A single day of delay in a Phase II or III study costs tens of thousands of USD in direct costs.Screen failures that drain the site
Candidates who don't qualify consume visits, staff and time from a site that is already at capacity.Sites with no capacity to recruit
Site teams are focused on running the study, not on going out to find patients.Why Latin America
The region where enrollment still has room
While traditional markets saturate, Latin America combines patient access, real diversity and data that regulators accept.Traditional markets have hit their ceiling
Interventional trials went from under 2,000 in 2000 to more than 22,000 in 2020, against an eligible population that did not grow at the same pace. At major centers in the US and Europe, dozens of studies compete for the same patients.A referral culture among physicians
A Latin American site enrolls roughly 12 participants per trial on average, against about 7 in the United States — some 70% more. Behind that number is a closer physician-patient bond, where raising a trial is a natural part of the clinical conversation.The diversity regulators are asking for
In US trials of new medicines, representation falls short of each group’s actual weight: 11% of participants were Hispanic against 18.7% of the population. The region brings that diversity within a single operating framework, and its data folds into international regulatory packages.How we work
From strategy to a candidate at the site
A process that absorbs the outreach work so the site only sees candidates with a real chance.1
Analysis and strategy
We study the protocol, the indication and the target population country by country to define where and how to search.2
Outreach campaigns
Communication tailored to each population and channel: digital media, our referring physician network and patient associations.3
Human pre-screening
Our team, trained on the protocol, contacts every lead and checks inclusion and exclusion criteria.4
Referral to the site
The site receives only pre-screened candidates, with their documentation, at a pace its schedule can absorb.Case studiesThe percentage is the share of study enrollment contributed by our campaigns over the period shown.
How much our campaign weighed in the study enrollment
Real studies in Latin America, with the share of enrollment our campaigns contributed and how long it took.76%
Sjögren's syndrome
10-month campaign · Latin America42%
Primary multiple sclerosis
11-month campaign · Latin America54%
Crohn's disease
9-month campaign · Latin America53%
Interstitial lung diseases
12-month campaign · Latin America47%
Lupus erythematosus (DLE/SCLE)
9-month campaign · Latin AmericaReach
Where our campaigns are running
How our active campaigns break down by country.- Brazil25%
- Argentina23%
- Mexico21%
- Chile18%
- Colombia11%
- Peru2%
Why Un Ensayo para Mí
A partner that knows the region
Technology, local insight and human support to accelerate enrollment.Purpose-built technology
Advanced analytics and automation to identify and engage the right patients for each protocol: shorter timelines, better enrollment quality, and the patient experience at the center of every decision.Hyper-localized recruitment
We tailor the strategy to each indication, country and population, combining real-world data with local insight into each country's health system, language and culture.AI-augmented human support
Local teams using AI-powered tools to support every candidate empathetically and in real time throughout the process.Owned channels
Beyond social media, we run our own patient database, a referring physician network, partnerships with molecular labs and active ties with patient associations.Quality over volume
We measure qualified candidates, not clicks: 28% of the patients we refer end up randomized, measured across every study already closed.Reporting and traceability
Full funnel visibility by country and by site, with current data to make decisions while the study runs.Compliance
Our information security management practices are aligned with the ISO 27001 standard.
Patient data handled to international standards
We work under Good Clinical Practice and the data protection frameworks international sponsors require.Let's set up a meeting
Tell us about your study
Leave your details and we'll set up a 30-minute call to go over the protocol and your recruitment options in the region.- We reply within 48 business hours.
- We set up a 30-minute call with the team that would run the project.
- If there's a fit, we put together a proposal with scope, timeline and costs.
